Press Release



Poxel announces that a Combined General Meeting
will be held on December 11, 2025 and the
availability of the preparatory documents

LYON, France, November 20, 2025 – POXEL SA (Euronext : POXEL -
FR0012432516), a clinical stage biopharmaceutical company developing innovative
treatments for chronic serious diseases with metabolic pathophysiology, including
metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic
disorders, today informs its shareholders that a Combined General Meeting will be
held on December 11, 2025, at 10:00 am CET at the Mercure Lyon Centre Château
Perrache Hotel, located at 12 Cours de Verdun-Rambaud Esplanade de la Gare,
69002 Lyon, and provides information on voting procedures.

All preparatory documents and information related to this General Meeting are
available to shareholders under legal and regulatory conditions and can be
accessed on the Company’s website in the “Annual General Meeting Documents”
section.

In accordance with current regulations, Poxel shareholders may cast their votes
before the General Meeting, starting from November 26, 2025, by mail, proxy, or
electronically, following the instructions in the meeting notice published in the
BALO on November 5, 2025, and reproduced in the convening notice which will be
published on November 26, 2025.

The option to vote or grant proxy electronically is available via the secure voting
platform Votacess, which will open on November 26, 2025, at 9:00 am (Paris time)
and close on December 10, 2025, at 3:00 pm (Paris time).

Voting instructions are also detailed in the practical guide available to shareholders
on the Company’s website.

For any questions regarding voting procedures, you may contact the Investor
Relations team by email: investors@poxelpharma.com.

Shareholders willing to follow the General Meeting but unable to attend in person
are invited to connect via the following link (the General Meeting will be held in
French): click here.

This live broadcast of the General Meeting will not allow remote voting or
questions via the chat feature on the platform used.




1
A replay of the General Meeting will be available on the Company’s website after
the meeting.


About Poxel SA

Poxel is a clinical stage biopharmaceutical company developing innovative
treatments for chronic serious diseases with metabolic pathophysiology,
including metabolic dysfunction-associated steatohepatitis (MASH) and rare
disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R-
pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In
rare diseases, development of PXL770, a first-in-class direct adenosine
monophosphate-activated protein kinase (AMPK) activator, is focused on the
treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic
kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel’s first-in-class product that
targets mitochondrial dysfunction, is now marketed for the treatment of type 2
diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and
sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma
for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon,
France, and has subsidiaries in Boston, and Tokyo, Japan.

For more information, please visit: www.poxelpharma.com

All statements other than statements of historical fact included in this press release
about future events are subject to (i) change without notice and (ii) factors beyond
the Company’s control. These statements may include, without limitation, any
statements preceded by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can
have,” “likely,” “should,” “would,” “could” and other words and terms of similar
meaning or the negative thereof. Forward-looking statements are subject to
inherent risks and uncertainties beyond the Company’s control that could cause
the Company’s actual results or performance to be materially different from the
expected results or performance expressed or implied by such forward-looking
statements. The Company does not endorse or is not otherwise responsible for the
content of external hyperlinks referred to in this press release.


Contacts - Investor relations / Media

NewCap
Aurélie Manavarere, Théo Martin / Arthur Rouillé
investors@poxelpharma.com
+33 1 44 71 94 94




2